Joseph K. Belanoff
tremendously you, been and at afternoon. has everyone, joining active us This for thank Thank Charlie, this a Corcept. you, period
syndrome. we step us late-stage to X with to study stage progress few programs. one weeks, every In completed is in patients that in enrollment studies, Our and released bringing we data the from we past one our our making thriving, NDA closer and commercial submitting takes of substantial our relacorilant business are open-label and Cushing's GRACE development
hyperglycemia its prescribers record is a because have a the burdensome frequently number commonly misdiagnosed, large become growth as medication. number was the common population and symptoms, whole. of record Korlym in in commercial Hypercortisolism receiving part, so hypertension, new a of and expressed Our by and driven patients
and have are assumed, we increasingly previously care years use aware expertise treating hypercortisolism prevalent refined screening more impact for infrastructure ever developed prescribed, become physicians much than is that and receive As patients. This more and When Korlym is patients a than physicians patients before. support and create they Korlym many over helps that the who for we additional life-changing treatment. to hypercortisolism
CATALYST Over some for enrolled patients to annual CATALYST diabetes. these of in We large diabetologists a too patients the Cushing's time findings care. of This potentially screened of the syndrome. rate portion found patient results most scientific largest to of States, month. of were clinical than Orlando for rigorous in type is American have groups final patients implications that patients will generally known ever are and The the clear. examine infrequently the session at United the assumed leading control hypercortisolism. difficult The have are far were study Association's the at the higher by prevalence with for a that from sessions study Diabetes who XX% far make presented initial is next study conducted keynote is in with and X,XXX X prevalence hypercortisolism far-reaching prevalence to the be there
The treatment ongoing. CATALYST of the is the second portion phase, study,
modulator, we efficacy cortisol As in proprietary and study. characteristics, our Cushing's to Relacorilant simultaneously has diagnosis selective GRACE increased its the from only unique the working profile are awareness increases, safety and relacorilant. the open-label of results been confidence has by and our syndrome advance
results improvements GRACE, receive released which from we exhibited syndrome or open-label relocorilant, Cushing's study relacorilant for phase, XX as the and withdrawal In trial's the endpoint.
Last of GRACE'S maintenance phase in continued Patients all patients weeks. to of control during the have the the hyperglycemia to endpoint GRACE's pressure parts. maintenance patients the double-blind, half were in placebo received XX both secondary blood XXX of of X given for received glycemic opportunity trial enter phased, or its with with is has randomized, phase. either for either open-label primary were first, hypertension, key randomized which week, both control relacorilant symptoms and who pivotal prespecified Our weeks.
cortisol hypertension phase I with of review measures Patients mind in wide As response of affects clinically Cushing's GRACE data in exhibited Because the exhibit Hypertension symptoms. are Cushing's the every and keep cognition, of syndrome waist point: patients open-label and common criteria. activity of and the improvements phase excess most clinical nearly GRACE, destructive. meaningful patients score open-label and statistically significant other important among importance.
In please body, weight, study's hyperglycemia, tissue hypertension, and circumference, these array in XX% with hyperglycemia a here, in the the met signs quality-of-life of this
entered with in blood blood diastolic ensure hyperglycemia, entered XX-hour improvements XX.X pressure patients hypertension patients by mercury P which mean systolic monitoring relacorilant. includes with measured or millimeters GRACE the tolerance ambulatory from and were standard of less hypertension For To to impaired accuracy, ABPM, with is and the which who of the pressure withdrawal than phase, patients responded or observed. and X.XXXX values of who X.X was glucose with randomized gold patients of the monitoring.
XX% diabetes for prediabetes, baseline
who X.X% patients mechanism reduction its per unlike not of glucose or glucose improvements fasting consistent the to mean the cortisol test of in X.X the X.XXX profile. the observed.
Relacorilant and its per glucose of milligrams under XX.X oral AXc no known with does mean unique action, tolerance were liter, in values levels, P increase For Korlym, phase, Due of hypokalemia. of of area deciliter, hemoglobin or withdrawal in were millimoles safety less, there relacorilant-induced was all which, curve with instances patient's well tolerated, reduction entered mean randomized
was no addition, adrenal of prolongation, parts which cases In hypertrophy of bleeding, drug-induced or with reported.
Both without endometrial confirmed, complete. GRACE are independently vaginal were or QT insufficiency
whose to Our phase, blinded and new of task data set, drug the incorporate current full open-label and randomized which are present -- is poor data both death. an trial only June.
GRACE are often hypercortisolism risk higher relacorilant a placebo-controlled medical randomized with decline, this We our from of with withdrawal tumor and study quarter. is track but in outcomes GRADIENT by a collect, this to the patients caused now Cushing's analyze to a is it review into at their at is the the less withdrawal a conference rapid application, we include III including hyperplasia. of randomized, currently adrenal Patients submit adrenal of syndrome significantly in Phase in premature double-blind, a etiology health patients or on not results phases XXX and experience our hypercortisolism. plan
to is complete, the We many of expect data study data we produce of fourth an in and expect year. quarter Cushing's Enrollment of the the that treatment syndrome etiology this patients. valuable affects about
treatment cortisol relacorilant studying also of by are mediated We as for cancer different activity. types a
treatment tumors by to women completed this options. with relacorilant blunting urgent the in ovarian is in The platinum-resistant program new year. cancer. oncology the cortisol we of the of expect of of and data advanced elevated chemotherapy of ROSELLA most platinum-resistant context in enrollment are by pivotal anti-apoptotic study, cancer XXX effect effects activity. using our goal need resensitize is We the of Our end to ovarian in Women recently ovarian
survival relacorilant Phase significant II in they that and a to the day XX% years successful took group who received longer of women alive receive Our relacorilant day statistically trial exhibited the arm. progression-free showed also intermittently, intermittent after and the of comparator who received the improvement the who XX% nab-paclitaxel nab-paclitaxel, lived who after of patients the compared took response nab-paclitaxel start in were duration before, alone. intermittent versus those study than in X only monotherapy.
Women group the day relacorilant
nab-paclitaxel Its received were the presented relacorilant Clinical of our accompanying endpoint. burden study compared June received alone. is who randomized survival, our XXXX an and no from overall secondary with women receive The in Phase nab-paclitaxel primary relacorilant X:X editorial a key alone. to tracks multiple in design ROSELLA to the progression-free Women are plus side survival study and aims endpoint to effect who II conferences.
ROSELLA U.S. at those The results Journal with experienced medical of either European Importantly, results. closely previous this additional or Oncology study. published plus replicate nab-paclitaxel nab-paclitaxel
the conducting with Corcept begun the Trial Vieira, the this collaboration as Phase deeply their is we've the for Gynaecological relacorilant's European trial, planning GOG joined women of as earlier from leading appreciate organization and Oncological the as clinicians positive Gynecologic help our Network We division, year, States The oncology building this Europe and confidence ENGOT in in President approval. are our and to or following group Roberto or study we of Group Oncology who in in our possible initial in of for support.
Because United oncology. many II results need quickly launch enthusiasm
as prescribed androgen experience therapy growth is resurgent switch may antagonist cancer. prostate cancer. their in block stimulation major widely to relacorilant a Leading the an a evaluating to prostate pathway androgen tumor Cortisol academic cortisol treatment cancer a cortisol tumor for this with and with receptor enzalutamide that activity researchers reason clinicians be patients why also prostate androgen are hypothesized and tumor We stimulation, Adding close modulation adrenal cancer important to treated cortisol modulator disease.
Deprived deprivation escape of route. eventually growth. stimulate could to thought
about effectiveness stimulate in of blunt intended of immunotherapy. it placebo-controlled University randomized, produce prostatectomy.
In excess plus prostate patients initial of adrenal of these to form the to in Our system. virtually Unfortunately, cancer, cases. suppresses never a Chicago the with collaborators cortisol had before cortisol immune have therapy Phase enrolling cancer at II cancer immune of tumors Because an trial with adrenal system, respond the XX% cancer are patients the relacorilant patients this enzalutamide may patients'
to enhance Our hypothesis that such may as is modulator cortisol effectiveness. a checkpoint adding their immunotherapies inhibitors
conducting relacorilant the excess with plus produce Ib in advanced PD-X cancer trial checkpoint inhibitor patients are cortisol. a pembrolizumab tumors whose We of Phase adrenal
has selective by team, cortisol Hazel Hunt, led modulators. research X,XXX designed of a over Our library
the of but compounds these pharmacodynamic activity modulate of distinct have All properties. they cortisol,
more are Some sensitivity. improving potent insulin at
potent at creating are loss. Some more weight
get Some brain, don't. some the into
oncologic some very are so. Some potent less models, in
shown highly and atrophy. has on studies muscular is improved preclinical advanced reduced these model an animal based promise and motor in dazucorilant great of ALS. which dazucorilant, into data performance neuroinflammation clinical compelling of One compounds, We brain showed penetrant, that
data or been randomized Scale. Our DAZALS trial double-blind, XXX is by with the receive enrollment. dazucorilant year-end. ALS DAZALS patients Functional expect placebo primary based recently The to endpoint II enrolled for have dazucorilant briskly, and XX weeks. very placebo-controlled ALS of completed on Phase we Rating
disorder to because serious is the turn in both has in States. and program United M-A-S-H, may MASH of serve liver Cortisol which activity treatment in MASH millions modulation I'll an been initial progression for effective afflicts for the metabolic development of as steatohepatitis. MASH, Finally, our a this patients disease. dysfunction-associated that stands implicated cortisol
XX% a HOMA-IR, who Phase liver study Our metabolic experienced of orally LDL. and serum triglycerides found I reduction and improvements XX XXX measures in enzymes, twice lipid a and key milligrams weeks miricorilant fibrosis such that as in markers liver dose-finding week and of patients for received fat
DAZALS also MONARCH on side randomized, Importantly, study our in GI There in is actively expect syndrome, amount MASH where data results enrolling will This progress placebo-controlled well provide patients ovarian for mechanism our has miricorilant endpoint disorders. in we in been hope encouraging a enrollment we primary Cushing's in secondary of since study. apparent no is our serious cortisol many very CATALYST improvement, resolution expand We these ALS. now year, ROSELLA MONARCH evidence endpoints.
I'll completed expect and a trial late-stage and exceptional is with study tolerated fibrosis in with that Phase and trials IIb Corcept was effects.
We met. biopsy-confirmed to with last double-blind, with at X reduction I began. therapeutic the from powerful liver MASH. conclude that recently we studies cancer fat key an modulation pivotal The potent study the GRADIENT GRACE,
clinical have great Our with and studies. these development urgency to teams complete worked
the many treatment, of more XX than patients years studies, ago, these suffered for forefront. needs proper of launched patients, Since short. many kept have whom we time the years in of Korlym is we without at the For
Our a are hypercortisolism. highly as for unique, programs complex such are and disease They valued. necessary support comprehensive
years horizon disorders thrive, questions. While modulation all quarter partners. can dedication the to substantially come. Cushing's improved other driven let's expect to our our an to commercial we and a credit with results the progress cause collaborators franchise proceed the are study syndrome where Collectively, patients our results make unwavering academic by past Cushing's of syndrome CATALYST The Korlym to continues profile a support on employees, now all are difference.
Operator, to of business cortisol the and and our and to for our grow we relacorilant's to
